XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' equity (deficit)
 6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Stockholders' equity (deficit)
8. Stockholders’ equity (deficit)
Warrants
As of June 30, 2023, the following table summarizes the status of our outstanding and exercisable warrants and related transactions since December 31, 2022 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):
 
 
  
Warrants Outstanding and exercisable
 
 
  
Warrants
 
  
Weighted Average
Exercise Price
 
  
Aggregate Intrinsic Value
 
  
Weighted Average
Remaining Contractual
Life (in Years)
 
As of January 1, 2023
      536      $ 13.10      $ 2,427        9.3  
Exercised
      (435 )       —          (634
)
 		      (4.5
)
 
Expired
      (2 )       —          —          —    
    
 
 
     
 
 
     
 
 
     
 
 
  
As of June 30, 2023
      99      $ 66.61      $ 1,793        4.8  
    
 
 
     
 
 
     
 
 
     
 
 
  
Share-based compensation payment plans
As of June 30, 2023, 269,207 
shares of common stock were subject to outstanding awards under our share-based payment award plans and inducement grants (calculated using the base number of PSUs that may vest). As of June 30, 2023,
321,717 shares of common stock were available for future grants of share-based payment awards under the TherapeuticsMD, Inc. 2019 Stock Incentive Plan.
 
The following table summarizes the status of our outstanding and exercisable options and related transactions (each adjusted to account for the Reverse Stock Split) since December 31, 2022 (in thousands, except weighed average exercise price and weighted average remaining contractual life data):
 
     Outstanding      Exercisable  
     Options
Awards		     Weighted
Average
Exercise
Price		      Aggregate
Intrinsic
Value		      Weighted
Average
Remaining
Contractual
Life
(in Years)		      Options
Awards		     Weighted
Average
Exercise
Price		      Aggregate
Intrinsic
Value		      Weighted
Average
Remaining
Contractual
Life
(in Years)		  
As of January 1, 2023
      172     $ 228.28        —          3.6        170     $ 229.43        —          3.6  
Granted
      —         —          —          —          —         —          —          —    
Exercised
      —         —          —          —          —         —          —          —    
Cancelled/Forfeited
      —         —          —          —          —         —          —          —    
Expired
      (90 )      203.84        —          3.3        (90 )      203.84        —          3.3  
    
 
 
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
As of June 30, 2023
      82     $ 255.03        —          3.5        80     $ 258.50        —          3.5  
    
 
 
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
The following table summarizes the status of our RSUs and related transactions (each adjusted to account for the Reverse Stock Split) since December 31, 2022 (in thousands, except weighed average grant date fair value):
 
 
  
RSUs awards outstanding
 
 
RSUs awards vested and not
settled
 
 
  
RSUs
 
 
Weighted
Average
Grant Date
Fair Value
 
  
Aggregate
Intrinsic
Value
 
 
RSUs
 
  
Weighted
Average
Grant Date
Fair Value
 
  
Aggregate
Intrinsic
Value
 
As of January 1, 2023
      246     $ 29.64        1,376       189       26.28      $ 1,059  
Granted
      120       5.12        185                           
Vested and settled
      (242 )      22.02        (1,758 )                          
Cancelled/Forfeited
      —         —        —                           
    
 
 
    
 
 
     
 
 
    
 
 
    
 
 
     
 
 
  
As of June 30, 2023
      124     $ 8.15        663       70       5.12      $ 288  
    
 
 
    
 
 
     
 
 
    
 
 
    
 
 
     
 
 
  
The following table summarizes the status of our PSUs and related transactions for each for the following years (each adjusted to account for the Reverse Stock Split) since December 31, 2022 (in thousands, except weighed average grant date fair value):

 
 
  
Outstanding
 
 
Vested and not settled
 
 
  
PSUs
(1)
 
 
Weighted
Average
Grant Date
Fair Value
 
  
Aggregate
Intrinsic
Value
 
 
PSUs
 
  
Weighted
Average
Grant Date
Fair Value
 
  
Aggregate
Intrinsic
Value
 
As of January 1, 2023
      100     $ 42.30        558        81       39.95      $ 450  
Granted
      —         —          —                              
Vested and settled
      (86 )      40.89        (479 )                          
Cancelled/Forfeited
      —         —          —                              
    
 
 
    
 
 
     
 
 
     
 
 
    
 
 
     
 
 
  
As of June 30, 2023
      14     $ 52.15        72        —       —      $ —  
    
 
 
    
 
 
     
 
 
     
 
 
    
 
 
     
 
 
  
 
(1)
The number of PSUs represents the base number of PSUs that
may
vest.
 
Share-based payment compensation cost
Share-based payment compensation expense for PSUs is based on 100% vesting which was a part of
 the
termination benefits for all employees who were terminated in 2022. We recorded share-based payment award compensation costs related to previously issued options, RSU and PSUs, as well as shares of common stock issued under our ESPP totaling $0.4 million and $2.2 million for the three months ended June 30, 2023 and 2022 respectively, and $0.9 million and $4.3 million for the six months ended June 30, 2023 and 2022 respectively.
As of June 30, 2023, we had $0.5 million of unrecognized share-based payment award compensation cost related to unvested options, RSUs and PSUs as well as shares issuable under our ESPP, which may be adjusted for future changes in forfeitures and is included as additional
paid-in
capital in the accompanying condensed consolidated balance sheets. No tax benefit was realized due to a continued pattern of net losses.
The unrecognized compensation cost as of June 30, 2023 of $0.5 million is expected to be recognized as share-based payment award compensation over a weighted average period of 0.6 years.